Protara Therapeutics, Inc. (TARA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. The company has no approved products and generates no revenue from product sales. Its primary development programs include TARA-002 (an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations) and IV Choline Chloride (an investigational therapy for patients on parenteral support).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(14.96) million | $(26.87) million | $(20.61) million |
| Loss Per Share (Diluted) | $(0.35) | $(0.65) | $(1.26) |
| Operating Expenses | $16.59 million | $30.71 million | $22.51 million |
| Research & Development | $10.77 million | $19.92 million | $14.14 million |
| General & Administrative | $5.82 million | $10.79 million | $8.38 million |
| Investment Income | $1.63 million | $3.36 million | $1.90 million |
| Cash & Cash Equivalents | $31.50 million | $31.50 million | $89.58 million |
| Marketable Debt Securities | $114.11 million | $114.11 million | $7.49 million |
| Total Liquidity (Cash + Investments) | $145.61 million | $145.61 million | $97.07 million |
| Working Capital | $115.33 million | $115.33 million | N/A |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2025, increased by $8.2 million (36%) compared to the same period in 2024. This was driven by a $5.8 million increase in R&D expenses and a $2.4 million increase in G&A expenses.
- R&D Spend Drivers: The increase in R&D was primarily due to site expansion and enrollment in the ADVANCED-2 NMIBC clinical trial and startup costs for the THRIVE-3 IV Choline Chloride trial.
- Investment Strategy: The company significantly increased its investment portfolio, purchasing $117.5 million in marketable debt securities during the first half of 2025, compared to no purchases in the same period in 2024. This resulted in higher interest and investment income ($3.36 million YTD 2025 vs. $1.90 million YTD 2024).
- Cash Position: While total liquidity remains strong at $145.6 million, unrestricted cash and cash equivalents decreased from $162.8 million at year-end 2024 to $31.5 million at June 30, 2025, as funds were deployed into marketable securities.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current financial resources are sufficient to satisfy estimated liquidity needs for at least twelve months from the date of filing. However, the company will need to raise additional capital to fully realize its plans.
- Clinical Milestones:
- TARA-002 (NMIBC): Interim data from the ADVANCED-2 trial showed a 100% complete response rate in a small cohort of BCG-Unresponsive patients. The company expects to present an interim analysis from approximately 25 six-month evaluable patients in Cohort B in Q1 2026.
- IV Choline Chloride: The company plans to initiate the registrational Phase 3 THRIVE-3 trial in Q3 2025. EU-CTR approval was received in July 2025, with enrollment expected in H2 2025.
- TARA-002 (LMs): An interim update from the STARBORN-1 trial is expected in Q4 2025.
- Risks: The company faces risks related to the success of clinical trials, regulatory approvals, and the ability to secure additional financing. There is no guarantee that the company will generate revenue in the near term or ever.
Key Facts for Investor Verification
- Cash Burn Rate: Verify the sustainability of the current cash position given the increased R&D spend and the timeline for the next capital raise.
- Clinical Trial Enrollment: Monitor the enrollment progress of the THRIVE-3 (IV Choline Chloride) and ADVANCED-2 (TARA-002) trials to ensure they meet the projected timelines for data readouts.
- Investment Portfolio: Review the composition and maturity of the $114.1 million in marketable debt securities to assess liquidity flexibility and exposure to interest rate changes.
- Dilution Potential: Note the existence of approximately 21.8 million potentially dilutive shares (warrants, options, and convertible preferred stock) outstanding as of June 30, 2025.